Oskar Hansson
Impact in
- Psychiatry and Mental health top 0.01%
- Dementia and Cognitive Impairment Research
- Physiology top 0.01%
- Alzheimer's disease research and treatments
Papers in
-
- Dementia and Cognitive Impairment Research 379
- Physiology 335
- Alzheimer's disease research and treatments 318
- Co-authors
- Kaj Blennow (224 shared papers)Henrik Zetterberg (194 shared papers)Niklas Mattsson-Carlgren (194 shared papers)Erik Stomrud (194 shared papers)Sebastian Palmqvist (178 shared papers)Lennart Minthon (98 shared papers)Shorena Janelidze (88 shared papers)Elisabet Londos (43 shared papers)
- Journals
- Alzheimer s & Dementia (187 papers)Theoria (47 papers)Alzheimer s Research & Therapy (45 papers)Brain (39 papers)Neurology (33 papers)
- Partner nations
- SwedenUnited StatesUnited Kingdom
In The Last Decade
Oskar Hansson
961 papers receiving 63.1k citations
Oskar Hansson's Hit Papers
Peers
Comparison fields: 5 of 226
- Psychiatry and Mental health 21.0k
- Physiology 22.8k
- Neurology 7.3k
- Biological Psychiatry 1.8k
- Neurology 7.9k
Countries citing papers authored by Oskar Hansson
This map shows the geographic impact of Oskar Hansson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oskar Hansson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oskar Hansson more than expected).
Fields of papers citing papers by Oskar Hansson
This network shows the impact of papers produced by Oskar Hansson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oskar Hansson. The network helps show where Oskar Hansson may publish in the future.
Co-authors
The 25 scholars most cited alongside Oskar Hansson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.0k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Donanemab in Early Symptomatic Alzheimer Disease Hit paper breakdown → | 2023 | 1732 |
| 2 | Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup Hit paper breakdown → | 2024 | 1408 |
| 3 | Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Hit paper breakdown → | 2006 | 1388 |
| 4 | Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders Hit paper breakdown → | 2020 | 1077 |
| 5 | Brain charts for the human lifespan Hit paper breakdown → | 2022 | 1043 |
| 6 | Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease Hit paper breakdown → | 2022 | 1018 |
| 7 | Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts Hit paper breakdown → | 2020 | 984 |
| 8 | Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia Hit paper breakdown → | 2020 | 948 |
| 9 | Biomarkers for neurodegenerative diseases Hit paper breakdown → | 2021 | 842 |
| 10 | Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity Hit paper breakdown → | 2017 | 675 |
| 11 | CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts Hit paper breakdown → | 2018 | 600 |
| 12 | Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology Hit paper breakdown → | 2019 | 596 |
| 13 | 2002 | 523 | |
| 14 | Four distinct trajectories of tau deposition identified in Alzheimer’s disease Hit paper breakdown → | 2021 | 521 |
| 15 | Plasma β-amyloid in Alzheimer’s disease and vascular disease Hit paper breakdown → | 2016 | 514 |
| 16 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers Hit paper breakdown → | 2017 | 511 |
| 17 | CSF and blood biomarkers for Parkinson's disease Hit paper breakdown → | 2019 | 511 |
| 18 | 2009 | 453 | |
| 19 | Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study Hit paper breakdown → | 2021 | 436 |
| 20 | The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease Hit paper breakdown → | 2022 | 435 |
About Oskar Hansson
Oskar Hansson is a scholar working on Psychiatry and Mental health, Physiology, Neurology, Neurology and Cognitive Neuroscience, having authored 1.0k papers that have together received 64.7k indexed citations. Recurring topics across this work include Dementia and Cognitive Impairment Research (379 papers), Alzheimer's disease research and treatments (318 papers), Parkinson's Disease Mechanisms and Treatments (77 papers), Functional Brain Connectivity Studies (65 papers), Advanced Neuroimaging Techniques and Applications (45 papers), Risk Perception and Management (40 papers), Neurological Disease Mechanisms and Treatments (36 papers) and Neurological disorders and treatments (30 papers). The work is most often cited by research in Psychiatry and Mental health (21.0k citations), Physiology (22.8k citations), Neurology (7.3k citations), Biological Psychiatry (1.8k citations) and Neurology (7.9k citations). Oskar Hansson has collaborated with scholars based in Sweden, United States and United Kingdom. Frequent co-authors include Kaj Blennow, Henrik Zetterberg, Niklas Mattsson-Carlgren, Erik Stomrud, Sebastian Palmqvist, Lennart Minthon, Shorena Janelidze, Elisabet Londos, Ruben A Smith and Shorena Janelidze. Their work appears in journals such as Alzheimer s & Dementia, Theoria, Alzheimer s Research & Therapy, Brain and Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.